Funder
Alzheimer’s Research UK
Psychiatry Consortium of the Medicines Discovery Catapult
National Institute for Health Research
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Psychiatry and Mental health,Neurology (clinical)
Reference127 articles.
1. Owen MJ, Sawa A, Mortensen PB. Schizophrenia. The Lancet. 2016;388(10039):86–97.
2. Knable MB, Weinberger DR. Dopamine, the prefrontal cortex and schizophrenia. J Psychopharmacol. 1997;11(2):123–31.
3. Goldman-Rakic PS, Castner SA, Svensson TH, Siever LJ, Williams GV. Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology. 2004;174(1):3–16.
4. Green MF, Kern RS, Heaton RK. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res. 2004;72(1):41–51.
5. Milev P, Ho B-C, Arndt S, Andreasen NC. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry. 2005;162(3):495–506.
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献